Dr. Sabine Heitzeneder’s research bridges the rational discovery of promising, tumor-restricted target antigens expressed on childhood cancer, that are absent from normal, vital tissue in the body and the robust pre-clinical development of adoptive cellular immunotherapies tailored to these antigens, that are suitable for phase I clinical testing in patients.